Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Quelling the storm: utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm.

Walsh KB, Teijaro JR, Rosen H, Oldstone MB.

Immunol Res. 2011 Oct;51(1):15-25. doi: 10.1007/s12026-011-8240-z. Review.

PMID:
21901448
2.

Animal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy.

Walsh KB, Teijaro JR, Brock LG, Fremgen DM, Collins PL, Rosen H, Oldstone MB.

J Virol. 2014 Jun;88(11):6281-93. doi: 10.1128/JVI.00464-14. Epub 2014 Mar 26.

3.

Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus.

Walsh KB, Teijaro JR, Wilker PR, Jatzek A, Fremgen DM, Das SC, Watanabe T, Hatta M, Shinya K, Suresh M, Kawaoka Y, Rosen H, Oldstone MB.

Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):12018-23. doi: 10.1073/pnas.1107024108. Epub 2011 Jun 29.

4.

Three phases of CD8 T cell response in the lung following H1N1 influenza infection and sphingosine 1 phosphate agonist therapy.

Matheu MP, Teijaro JR, Walsh KB, Greenberg ML, Marsolais D, Parker I, Rosen H, Oldstone MB, Cahalan MD.

PLoS One. 2013;8(3):e58033. doi: 10.1371/journal.pone.0058033. Epub 2013 Mar 22.

5.

Local not systemic modulation of dendritic cell S1P receptors in lung blunts virus-specific immune responses to influenza.

Marsolais D, Hahm B, Edelmann KH, Walsh KB, Guerrero M, Hatta Y, Kawaoka Y, Roberts E, Oldstone MB, Rosen H.

Mol Pharmacol. 2008 Sep;74(3):896-903. doi: 10.1124/mol.108.048769. Epub 2008 Jun 24.

6.

Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection.

Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, Roberts E, Scott F, Martinborough E, Peach R, Oldstone MB, Rosen H.

Cell. 2011 Sep 16;146(6):980-91. doi: 10.1016/j.cell.2011.08.015.

7.

Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection.

Oldstone MB, Teijaro JR, Walsh KB, Rosen H.

Virology. 2013 Jan 5;435(1):92-101. doi: 10.1016/j.virol.2012.09.039. Review.

8.

Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection.

Teijaro JR, Walsh KB, Rice S, Rosen H, Oldstone MB.

Proc Natl Acad Sci U S A. 2014 Mar 11;111(10):3799-804. doi: 10.1073/pnas.1400593111. Epub 2014 Feb 26.

9.

Inhibition of the inflammatory cytokine tumor necrosis factor-alpha with etanercept provides protection against lethal H1N1 influenza infection in mice.

Shi X, Zhou W, Huang H, Zhu H, Zhou P, Zhu H, Ju D.

Crit Care. 2013 Dec 27;17(6):R301. doi: 10.1186/cc13171.

10.

The Flavonoid Isoliquiritigenin Reduces Lung Inflammation and Mouse Morbidity during Influenza Virus Infection.

Traboulsi H, Cloutier A, Boyapelly K, Bonin MA, Marsault É, Cantin AM, Richter MV.

Antimicrob Agents Chemother. 2015 Oct;59(10):6317-27. doi: 10.1128/AAC.01098-15. Epub 2015 Jul 27.

11.
12.

The role of alpha/beta and gamma interferons in development of immunity to influenza A virus in mice.

Price GE, Gaszewska-Mastarlarz A, Moskophidis D.

J Virol. 2000 May;74(9):3996-4003.

13.

Saikosaponin A inhibits influenza A virus replication and lung immunopathology.

Chen J, Duan M, Zhao Y, Ling F, Xiao K, Li Q, Li B, Lu C, Qi W, Zeng Z, Liao M, Liu Y, Chen W.

Oncotarget. 2015 Dec 15;6(40):42541-56. doi: 10.18632/oncotarget.6448.

14.

Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza.

London NR, Zhu W, Bozza FA, Smith MC, Greif DM, Sorensen LK, Chen L, Kaminoh Y, Chan AC, Passi SF, Day CW, Barnard DL, Zimmerman GA, Krasnow MA, Li DY.

Sci Transl Med. 2010 Mar 17;2(23):23ra19. doi: 10.1126/scitranslmed.3000678.

15.

An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.

Khalil SM, Tonkin DR, Snead AT, Parks GD, Johnston RE, White LJ.

J Virol. 2014 Aug;88(16):9182-96. doi: 10.1128/JVI.00327-14. Epub 2014 Jun 4.

16.

Protection of ferrets from pulmonary injury due to H1N1 2009 influenza virus infection: immunopathology tractable by sphingosine-1-phosphate 1 receptor agonist therapy.

Teijaro JR, Walsh KB, Long JP, Tordoff KP, Stark GV, Eisfeld AJ, Kawaoka Y, Rosen H, Oldstone MB.

Virology. 2014 Mar;452-453:152-7. doi: 10.1016/j.virol.2014.01.003. Epub 2014 Jan 31.

17.

CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection.

Lin KL, Sweeney S, Kang BD, Ramsburg E, Gunn MD.

J Immunol. 2011 Jan 1;186(1):508-15. doi: 10.4049/jimmunol.1001002. Epub 2010 Nov 22.

18.

CLEC5A-Mediated Enhancement of the Inflammatory Response in Myeloid Cells Contributes to Influenza Virus Pathogenicity In Vivo.

Teng O, Chen ST, Hsu TL, Sia SF, Cole S, Valkenburg SA, Hsu TY, Zheng JT, Tu W, Bruzzone R, Peiris JS, Hsieh SL, Yen HL.

J Virol. 2016 Dec 16;91(1). pii: e01813-16. Print 2017 Jan 1.

19.

New insights into the effects and mechanism of a classic traditional Chinese medicinal formula on influenza prevention.

Chen H, Jie C, Tang LP, Meng H, Li XB, Li YB, Chen LX, Yan C, Kurihara H, Li YF, He RR.

Phytomedicine. 2017 Apr 15;27:52-62. doi: 10.1016/j.phymed.2017.02.004. Epub 2017 Feb 14.

PMID:
28314479
20.

Influenza A (H1N1) virus infection triggers severe pulmonary inflammation in lupus-prone mice following viral clearance.

Slight-Webb SR, Bagavant H, Crowe SR, James JA.

J Autoimmun. 2015 Feb;57:66-76. doi: 10.1016/j.jaut.2014.12.003. Epub 2015 Jan 3.

Supplemental Content

Support Center